论文部分内容阅读
曲妥珠单抗(trastuzumab,Herceptin)是罗氏公司开发的针对HER2蛋白的单克隆抗体。本研究对比了多西他赛(docetaxel)和长春瑞滨(vinorebine)对早期乳腺癌的辅助治疗效果,并且对其中过度表达HER2/neu的女性患者联用曲妥珠单抗与不用曲妥珠单抗治疗的疗效进行比较。随机挑选1010名
Trastuzumab (Herceptin) is a monoclonal antibody developed by Roche for the HER2 protein. This study compared adjuvant therapies for docetaxel and vinorebine in early-stage breast cancer and compared trastuzumab with trastuzumab in women who over-expressed HER2 / neu The efficacy of mAb therapy was compared. 1010 randomly selected